28 December 2009 in Oncology Reports
Hepatocellular carcinoma (HCC) is an aggressive cancer with a dismal outcome largely due to metastasis and postsurgical recurrence. Thus, the inhibition of invasion and metastasis is of great importance in its therapies. Medicinal plants or ethnopharmacology used in folklore medicine continue to be an important source of discovery and development of novel or potential therapeutic agents for treatment of cancer. Chrysanthemum indicum, one of the medicinal plants or ethnopharmacology, is being used for treatment of many diseases including cancer. However, this plant molecular mechanisms underlining the anti-metastatic effects have not been well documented. In this study, Chrysanthemum indicum ethanolic extract (CIE) significantly suppressed proliferation and invasion of MHCC97H cells, one of the HCC cell lines with high metastatic potential, in a dose-dependent manner. CIE markedly decreased MMP-2 and MMP-9 expression, increased simultaneously TIMP-1, and TIMP-2 expression further restoring their balance in the cancer cells. The present study indicates that CIE reduced MHCC97H cell metastatic capability, in part at least, through decrease of the MMP expression, simultaneous increase of the TIMP expression, further restoring their balance as therapeutic target in HCC. It is suggested that Chrysanthemum indicum is a potential novel therapeutic medicinal plant for treatment of HCC or cancer invasion and metastasis.
24 May 2012 in Journal of Clinical Laboratory Analysis
23 November 2009 in Oncology Reports
Increasing data indicate that stress hormones and their corresponding receptors play an important role in the carcinogenesis and progression of hepatocellular carcinoma (HCC). However, there is presently no study investigating the influence of stress hormones in correlation with β2-AR on human HCC cells. We examined the expression of α1- and β-ARs in human HCC cell line HepG2 and MHCC97H cells in comparison with that in human normal hepatic cell line HL-7702 cells (L-02), and the influence of isoproterenol (ISO) on the growth of these HCC cells using blocking agents in correlation with β2-AR and its downstream signaling pathways. We found that α1-AR was down-regulated and β2-AR was up-regulated in HepG2 and MHCC97H cells. ISO dose-dependently promoted the growth of both HepG2 and MHCC97H cells. ISO-induced growth and survival of HCC cells were effectively attenuated by ICI 118551, U0126 and PD153035, but not by H-89 or LY294002. ISO transiently activated MAPK/ERK1/2 in tumor cells which could be blocked either by ICI 118551 or U0126, but not by H-89, LY294002, or PD153035. These findings indicate that ISO mimicking a mitogen promoted the growth of HepG2 and MHCC97H cells via β2-AR-mediated activation of both MAPK/ERK1/2 dependent and independent signaling pathways, and ISO activated MAPK/ERK1/2 by an EGFR-independent mechanism.
1 January 1994 in Oncology Reports
Modulation of the activity of tumor suppressor p53 is a key event in the replication of many viruses. They could manipulate p53 function through modification of phosphorylation for their own purpose. However, there are scarce data on the relationship between high risk human papillomavirus (HPV) E6 protein and p53 phosphorylation status. Therefore, we used a mammalian green fluorescence protein (GFP) expression system to express HPV-16E6 with GFP fusion proteins in wild-type p53 cell lines, 293T, MCF-7, and SMMC-7721 to trace the traffic and subcellular location of E6 protein. By immunoblotting, we determined the positive phosphorylated sites of p53 in the context of HPV-16E6. Using immunofluorescence techniques, we observed the distribution of phosphorylated p53 in all the cells we used. In conclusion, HPV-16E6 was predominantly located in nuclei of wild-type p53 cells, and it was able to induce phosphorylation of p53 at multiple sites, such as Ser15, Ser20, and Ser392. The level and time of these phosphorylated sites of p53 were different in HPV-16E6 expressing cells. Furthermore, the phosphorylated p53 was localized in the nuclei together with HPV-16E6.